Restrictive access to clopidogrel and mortality following coronary stent implantation.

Restrictive access to clopidogrel and mortality following coronary stent implantation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Restrictive access to clopidogrel and mortality following coronary stent implantation. Abstract Text:

Odile Sheehy,Jacques LeLorier,Stéphane Rinfret,Odile Sheehy,Jacques LeLorier,Stéphane Rinfret,

BACKGROUND: In Canada, access to clopidogrel is restricted by most provincial drug insurance plans in order to contain costs. Until April 2007, the Régie de l'assurance maladie du Québec (RAMQ) Prescription Drug Insurance Plan reviewed special access forms before approving reimbursement for clopidogrel prescriptions. We investigated the impact of this restrictive process on patient's filling of prescriptions and on all-cause mortality following coronary stenting. METHODS: We analyzed prescriptions filled and all-cause mortality in the year following a percutaneous coronary intervention among patients who underwent stent implantation between January 2000 and September 2004. We obtained administrative data from the RAMQ databases. We included patients who filled at least 1 prescription for a nonrestricted cardiovascular drug after hospital discharge. We used Cox proportional models to compare mortality rates as a function of delayed or absent outpatient clopidogrel therapy. RESULTS: Of 13,663 patients, 1571 (11.5%) did not fill any clopidogrel prescription despite filling at least 1 nonrestricted cardiovascular drug prescription after a percutaneous coronary intervention, and 1174 (8.6%) patients filled their clopidogrel prescription with a delay of at least 1 day (median delay 5 days) after filling the nonrestricted cardiovascular drug prescription. After controlling for pertinent covariables, not filling a clopidogrel prescription (hazard ratio [HR] 1.70, 95% confidence interval [CI] 1.35-2.15) and filling with a delay (HR 1.34, 95% CI 1.01-1.80) were associated with a significant increase in all-cause mortality. INTERPRETATION: Restricted access to clopidogrel was associated with about 20% of patients either not receiving clopidogrel or receiving therapy after a delay. Delay or absence of clopidogrel therapy increased the risk of all-cause mortality after percutaneous coronary intervention with stenting.

Restrictive access to clopidogrel and mortality following coronary stent implantation. Publishing Authors By Initials

O Sheehy,J LeLorier,S Rinfret,O Sheehy,J LeLorier,S Rinfret,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Restrictive access to clopidogrel and mortality following coronary stent implantation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: CMAJ : Canadian Medical Association journal = jour

VOLUME: 178

Page Numbers: 413-20

Journal Abbreviation:

ISSN: 1488-2329

DAY: 12

MONTH: Feb

YEAR: 2008

Restrictive access to clopidogrel and mortality following coronary stent implantation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9711805

Restrictive access to clopidogrel and mortality following coronary stent implantation. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Restrictive access to clopidogrel and mortality following coronary stent implantation. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Restrictive access to clopidogrel and mortality following coronary stent implantation.

AFFILIATION: Pharmaco-economics and pharmaco-epidemiology unit, Centre Hospitalier de l'Université de Montréal Research Centre, Université de Montréal, Montréal, Que.

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: CMAJ

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Restrictive access to clopidogrel and mortality following coronary stent implantation Related Publications

• Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues.
• Interference of biochemically important reducing agents with the diazotation of sulfanilamide.
• Left main coronary artery occlusion with myocardial infarction in a cocaine user. Successful angioplasty with a drug-eluting stent.
• Restrictive access to clopidogrel and mortality following coronary stent implantation.
• The unresolved issues with risk stratification and management of patients with coronary artery disease undergoing major vascular surgery: [Questions non resolues concernant la stratification du risque et la prise en charge des patients atteints de maladie
• [Not Available.]
• [Not Available.]